Thursday, 9 February 2006
Therapeutic Goods Amendment (Repeal of Ministerial Responsibility for Approval of Ru486) Bill 2005
I have a question of the movers of the motion. I understand that the trans-Tasman agreement for harmonisation of therapeutic products is currently under negotiation between Australia and New Zealand and is going to merge the TGA and the counterpart New Zealand organisation. In recognition of some basic administrative differences between Australia and New Zealand, and, given the potential different approaches in some regulatory activities between the two countries, can the movers of the bill please explain what the effect of this is going to be, particularly in the light of the amendments now being raised?